124 related articles for article (PubMed ID: 15250038)
1. Current trends in quantitative structure activity relationships on FXa inhibitors: evaluation and comparative analysis.
Kontogiorgis CA; Hadjipavlou-Litina D
Med Res Rev; 2004 Nov; 24(6):687-747. PubMed ID: 15250038
[TBL] [Abstract][Full Text] [Related]
2. Current trends in QSAR on NO donors and inhibitors of nitric oxide synthase (NOS)*.
Kontogiorgis CA; Hadjipavlou-Litina D
Med Res Rev; 2002 Jul; 22(4):385-418. PubMed ID: 12111751
[TBL] [Abstract][Full Text] [Related]
3. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors.
Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Isobe Y; Furugohri T; Kanno H
Bioorg Med Chem Lett; 2007 Aug; 17(16):4683-8. PubMed ID: 17555959
[TBL] [Abstract][Full Text] [Related]
4. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
[TBL] [Abstract][Full Text] [Related]
5. Lipoxygenase inhibitors: a comparative QSAR study review and evaluation of new QSARs.
Pontiki E; Hadjipavlou-Litina D
Med Res Rev; 2008 Jan; 28(1):39-117. PubMed ID: 17191217
[TBL] [Abstract][Full Text] [Related]
6. Thromboxane synthase inhibitors and thromboxane A2 receptor antagonists: a quantitative structure activity relationships (QSARs) analysis.
Kontogiorgis C; Hadjipavlou-Litina D
Curr Med Chem; 2010; 17(28):3162-214. PubMed ID: 20666724
[TBL] [Abstract][Full Text] [Related]
7. Prediction of factor Xa inhibitors by machine learning methods.
Lin HH; Han LY; Yap CW; Xue Y; Liu XH; Zhu F; Chen YZ
J Mol Graph Model; 2007 Sep; 26(2):505-18. PubMed ID: 17418603
[TBL] [Abstract][Full Text] [Related]
8. (R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode.
Mueller MM; Sperl S; Stürzebecher J; Bode W; Moroder L
Biol Chem; 2002; 383(7-8):1185-91. PubMed ID: 12437104
[TBL] [Abstract][Full Text] [Related]
9. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.
Qiao JX; Chang CH; Cheney DL; Morin PE; Wang GZ; King SR; Wang TC; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2007 Aug; 17(16):4419-27. PubMed ID: 17588746
[TBL] [Abstract][Full Text] [Related]
10. Quantitative structure activity relationship studies of aryl heterocycle-based thrombin inhibitors.
Deswal S; Roy N
Eur J Med Chem; 2006 Nov; 41(11):1339-46. PubMed ID: 16884829
[TBL] [Abstract][Full Text] [Related]
11. Cytokines in terms of QSAR. Review, evaluation and comparative studies.
Konstantinidou M; Hadjipavlou-Litina D
SAR QSAR Environ Res; 2013 Nov; 24(11):883-962. PubMed ID: 24099567
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
14. Factor Xa inhibitors: next-generation antithrombotic agents.
Pinto DJ; Smallheer JM; Cheney DL; Knabb RM; Wexler RR
J Med Chem; 2010 Sep; 53(17):6243-74. PubMed ID: 20503967
[No Abstract] [Full Text] [Related]
15. Anthranilamide inhibitors of factor Xa.
Mendel D; Marquart AL; Joseph S; Waid P; Yee YK; Tebbe AL; Ratz AM; Herron DK; Goodson T; Masters JJ; Franciskovich JB; Tinsley JM; Wiley MR; Weir LC; Kyle JA; Klimkowski VJ; Smith GF; Towner RD; Froelich LL; Buben J; Craft TJ
Bioorg Med Chem Lett; 2007 Sep; 17(17):4832-6. PubMed ID: 17624775
[TBL] [Abstract][Full Text] [Related]
16. Validated quantitative structure-activity relationship analysis of a series of 2-aminothiazole based p56(Lck) inhibitors.
Li J; Du J; Xi L; Liu H; Yao X; Liu M
Anal Chim Acta; 2009 Jan; 631(1):29-39. PubMed ID: 19046675
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors.
Vaidya M; Weigt M; Wiese M
Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
[TBL] [Abstract][Full Text] [Related]
20. Comparative binding energy analysis considering multiple receptors: a step toward 3D-QSAR models for multiple targets.
Murcia M; Morreale A; Ortiz AR
J Med Chem; 2006 Oct; 49(21):6241-53. PubMed ID: 17034130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
